Ocugen Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ocugen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCGN, but not buy additional shares or sell existing shares.
View analyst ratings for Ocugen or view top-rated stocks.

Wall Street analysts have given Ocugen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocugen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ocugen is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Ocugen.

Ocugen will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Ocugen, Inc. (NASDAQ:OCGN) issued its quarterly earnings results on Friday, May, 7th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.50 by $0.54.
View Ocugen's earnings history.

Ocugen's stock was trading at $0.3612 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCGN stock has increased by 1,851.8% and is now trading at $7.05.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12 month price targets for Ocugen's stock. Their forecasts range from $4.50 to $11.00. On average, they expect Ocugen's share price to reach $7.66 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Ocugen or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ocugen include Exelixis (EXEL), Recursion Pharmaceuticals (RXRX), Adaptive Biotechnologies (ADPT), Vir Biotechnology (VIR), Abcam (ABCM), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Sana Biotechnology (SANA), Allogene Therapeutics (ALLO), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Editas Medicine (EDIT) and Translate Bio (TBIO).
View all of OCGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), FuelCell Energy (FCEL), Biocept (BIOC), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM) and Carnival Co. & (CCL).

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Ocugen's stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.10%), New York State Common Retirement Fund (0.08%), Victory Capital Management Inc. (0.03%), Arizona State Retirement System (0.03%), Golden Green Inc. (0.02%) and Cutler Group LP (0.00%). Company insiders that own Ocugen stock include Christopher Dold, Daniel Purefoy, Howard C Draft, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends for Ocugen.

OCGN stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., New York State Common Retirement Fund, Arizona State Retirement System, Golden Green Inc., Victory Capital Management Inc., Cutler Group LP, Zurcher Kantonalbank Zurich Cantonalbank , and Creative Financial Designs Inc. ADV. Company insiders that have bought Ocugen stock in the last two years include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian, and Shankar Musunuri.
View insider buying and selling activity for Ocugen or or view top insider-buying stocks.

Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCGN stock can currently be purchased for approximately $7.05.

Ocugen has a market capitalization of $1.40 billion and generates $42.62 million in revenue each year. The company earns $-21,820,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

Ocugen employs 15 workers across the globe.

The official website for Ocugen is ocugen.com.

Ocugen is headquartered at 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355.

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected]